Observational studyJournal of Crohn's & colitis2021

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.

Lauranne A A P Derikx et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.